{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:06:51Z","timestamp":1763017611211},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.pcad.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T01:45:30Z","timestamp":1454550330000},"page":"495-504","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis"],"prefix":"10.1016","volume":"58","author":[{"given":"Marzia","family":"Lotrionte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi M.","family":"Biasucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 4","key":"10.1016\/j.pcad.2016.02.001_bb0005","first-page":"70","article-title":"Fifty years of progress in chronic disease epidemiology and control","volume":"60","author":"Remington","year":"2011","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.pcad.2016.02.001_bb0010","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0015","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/eurheartj\/eht356","article-title":"Cardiovascular disease in Europe: epidemiological update","volume":"34","author":"Nichols","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.02.001_bb0020","doi-asserted-by":"crossref","first-page":"h4970","DOI":"10.1136\/bmj.h4970","article-title":"Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database","volume":"351","author":"Ait Ouakrim","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2016.02.001_bb0025","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0035","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/eurheartj\/ehv220","article-title":"Cardiovascular diseases in populations: secular trends and contemporary challenges-Geoffrey Rose lecture, European Society of Cardiology meeting 2014","volume":"36","author":"Roger","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.02.001_bb0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.canep.2015.06.003","article-title":"Trends in mortality after cancer diagnosis: a nationwide cohort study over 45 years of follow-up in Sweden by country of birth","volume":"39","author":"Abdoli","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0045","article-title":"Trends in site- and sex-specific cancer mortality between 1979 and 2010 in Belgium compared with Europe using WHO data","author":"Vanthomme","year":"2015","journal-title":"J Public Health (Oxf)"},{"issue":"Suppl. 1","key":"10.1016\/j.pcad.2016.02.001_bb0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.24095\/hpcdp.35.S1.02","article-title":"Cancer incidence in Canada: trends and projections (1983\u20132032)","volume":"35","author":"Xie","year":"2015","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"10.1016\/j.pcad.2016.02.001_bb0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1636.17894","article-title":"Recent trends in cancer incidence: impact of risk factors, diagnostic activities and data quality of registration","volume":"100","author":"Dehler","year":"2014","journal-title":"Tumori"},{"issue":"0","key":"10.1016\/j.pcad.2016.02.001_bb0060","doi-asserted-by":"crossref","first-page":"0","DOI":"10.5301\/tj.5000430","article-title":"Cancer mortality trend analysis in Italy, 1980\u20132010, and predictions for 2015","volume":"0","author":"Rosso","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.pcad.2016.02.001_bb0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrclinonc.2015.36","article-title":"Epidemiology: cancer survival: global variation and long-term trends","volume":"12","author":"Lyratzopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0070","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin. A historical and contemporary therapeutic overview","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.02.001_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.pcad.2016.02.001_bb0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cct.2013.09.014","article-title":"Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial","volume":"36","author":"ASPREE Investigator Group","year":"2013","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.pcad.2016.02.001_bb0090","first-page":"254","article-title":"Chemopreventive effects of aspirin at a glance","volume":"1855","author":"Usman","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pcad.2016.02.001_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"26","author":"Cuzick","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0100","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0105","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0110","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(09)60243-9","article-title":"Aspirin, salicylates, and cancer","volume":"373","author":"Elwood","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0115","series-title":"Evidence Synthesis No. 131","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force","author":"Guirguis-Blake","year":"2015"},{"key":"10.1016\/j.pcad.2016.02.001_bb0120","series-title":"AHRQ Publication No. 13-05193-EF-1","article-title":"Aspirin use in adults: cancer, all-cause mortality, and harms. A systematic evidence review for the U.S. Preventive Services Task Force. Evidence synthesis no. 132","author":"Whitlock","year":"2015"},{"key":"10.1016\/j.pcad.2016.02.001_bb0125","article-title":"Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Evidence synthesis no. 133","author":"Chubak","year":"2015"},{"key":"10.1016\/j.pcad.2016.02.001_bb0130","article-title":"Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Evidence synthesis no. 68","author":"Wolff","year":"2009"},{"key":"10.1016\/j.pcad.2016.02.001_bb0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.10451","article-title":"Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials","volume":"75","author":"Serebruany","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0140","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2016.02.001_bb0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2016.02.001_bb0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2016.02.001_bb0155","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2036.1999.00470.x","article-title":"Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?","volume":"13","author":"Cole","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pcad.2016.02.001_bb0165","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2036.1999.00588.x","article-title":"Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions","volume":"13","author":"Dammann","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pcad.2016.02.001_bb0170","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s002280050539","article-title":"Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects","volume":"54","author":"Bode-B\u00f6ger","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0175","series-title":"Network meta-analysis: evidence synthesis with mixed treatment comparison","year":"2014"},{"key":"10.1016\/j.pcad.2016.02.001_bb0180","series-title":"Umbrella reviews. Evidence synthesis with overviews of reviews and meta-epidemiologic studies","year":"2016"},{"key":"10.1016\/j.pcad.2016.02.001_bb0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"Peto","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.pcad.2016.02.001_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","author":"Physician's Health Study","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0195","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diab.38.4.491","article-title":"Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial","volume":"38","author":"The DAMAD Study Group","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.pcad.2016.02.001_bb0200","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators","volume":"268","author":"ETDRS Investigators","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.02.001_bb0205","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council\u2019s General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project","volume":"357","author":"de Gaetano","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0220","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0225","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.02.001_bb0230","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2016.02.001_bb0235","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.02.001_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17430","article-title":"Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews","volume":"17","author":"Sutcliffe","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.pcad.2016.02.001_bb0245","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1093\/eurheartj\/eht287","article-title":"Is aspirin useful in primary prevention?","volume":"34","author":"Cleland","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.02.001_bb0250","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1093\/eurheartj\/eht058","article-title":"Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?","volume":"34","author":"Patrono","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.02.001_bb0255","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0260","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/clc.22394","article-title":"Reducing cardiovascular and cancer risk: how to address global primary prevention in clinical practice","volume":"38","author":"Battistoni","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081970","article-title":"Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials","volume":"8","author":"Sutcliffe","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pcad.2016.02.001_bb0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1345\/aph.18325","article-title":"Risk of gastric injury with enteric- versus nonenteric-coated aspirin","volume":"36","author":"Banoob","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pcad.2016.02.001_bb0275","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.2042-7158.1984.tb04394.x","article-title":"Absorption of acetylsalicylic acid from enteric-coated tablets in relation to gastric emptying and in-vivo disintegration","volume":"36","author":"Bogentoft","year":"1984","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0280","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/HYPERTENSIONAHA.114.04980","article-title":"Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial","volume":"65","author":"Bonten","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2016.02.001_bb0285","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1160\/TH14-05-0453","article-title":"Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial","volume":"112","author":"Bonten","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcad.2016.02.001_bb0290","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pcad.2016.02.001_bb0295","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcad.2016.02.001_bb0300","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jacc.2014.05.049","article-title":"Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry","volume":"64","author":"Mayer","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0305","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/heartjnl-2014-306342","article-title":"Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women","volume":"101","author":"van Kruijsdijk","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2016.02.001_bb0310","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1093\/eurheartj\/ehv251","article-title":"The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study","volume":"36","author":"Mortensen","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.02.001_bb0315","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bpg.2011.09.001","article-title":"Identification and chemoprevention in subjects at moderate risk of colorectal cancer","volume":"25","author":"Benamouzig","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3122\/jabfm.2014.01.130040","article-title":"Colorectal cancer predicted risk online (CRC-PRO) calculator using data from the multi-ethnic cohort study","volume":"27","author":"Wells","year":"2014","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0325","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3949\/ccjm.80a.12146","article-title":"Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events","volume":"80","author":"Park","year":"2013","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0330","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0335","series-title":"AHRQ Publication No. 12(14)-EHC149-EF","author":"Puhan","year":"2013"},{"key":"10.1016\/j.pcad.2016.02.001_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127194","article-title":"Aspirin for primary prevention of cardiovascular disease and cancer. A benefit and harm analysis","volume":"10","author":"Stegeman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pcad.2016.02.001_bb0345","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0350","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2015.01.014","article-title":"Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012)","volume":"115","author":"Fang","year":"2015","journal-title":"Am J Cardiol"},{"issue":"61 Suppl.","key":"10.1016\/j.pcad.2016.02.001_bb0355","first-page":"11","article-title":"Recommended use of aspirin and other antiplatelet medications among adults\u2014National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005\u20132008","author":"George","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.pcad.2016.02.001_bb0360","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(15)00469-9","article-title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","volume":"387","author":"Khatib","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020353","article-title":"Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease","volume":"2","author":"Stafford","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0370","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jacc.2014.10.035","article-title":"Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry","volume":"65","author":"Hira","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0375","first-page":"525","article-title":"Aspirin for primary prevention of CVD: are the right people using it?","volume":"61","author":"VanWormer","year":"2012","journal-title":"J Fam Pract"},{"key":"10.1016\/j.pcad.2016.02.001_bb0380","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.02.001_bb0385","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijcard.2014.12.091","article-title":"Aspirin underuse, non-compliance or cessation: definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease","volume":"182","author":"Biondi-Zoccai","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2016.02.001_bb0390","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"378","author":"Burn","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0395","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/archinte.167.6.562","article-title":"Long-term aspirin use and mortality in women","volume":"167","author":"Chan","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2016.02.001_bb0400","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.02.001_bb0405","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T07:44:40Z","timestamp":1567583080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062016300093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0033062016300093"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2016.02.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}